
category:news
Preserving muscle: GLP1s with Bimagrumab
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
category:news
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
company:novo-nordisk
Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
category:news
Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.
drug:eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
category:side-effects
A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
company:eli-lilly
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
research
Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.
company:roche
We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.
category:news
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
malady:addiction
We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.
drug:retatrutide
We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.
category:benefits
We look into the anti-inflammatory effects of GLP1s and their effects on issues like psoriasis and infertility.